Company intelligence / Profile preview

Zhejiang Youya Biotechnology

Zhejiang Sheng, China

Ownership: Private
Development stage: Other

Overview

Allogeneic dental pulp mesenchymal stem cell therapy has reached Phase 2 for chronic periodontitis and was investigated in Phase 1/2 for severe COVID-19 pneumonia; clinical data pending publication

Therapeutic areas: Infectious Diseases
Modalities: Stem cell therapyCell therapyAllogeneic mesenchymal stem cell therapy
Industry: Biotech

Partnerships

Beijing SH Bio-Tech CorporationBeijing Sanyouli Heze Biological Technology Co. Ltd.

Beyond the preview

Go deeper on Zhejiang Youya Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhejiang Youya Biotechnology.

Explore the full profile